Study Information

This clinical study requires healthy Caucasian male participants, aged 21 – 50 years old.

The purpose of this clinical study is to compare pharmacokinetic and pharmacodynamic data between healthy Japanese and Caucasian participants. This medication is currently available in EU and USA and with the help of this Phase 1 Bridging Study may soon be available for use in Japan as well.

The medication is to treat Polycythemia Vera, a rare blood condition in which a genetic mutation in bone marrow leads to an overproduction of Red Blood Cells. This causes a thickening of the blood leading to blood clots and haemorrhaging.


Participants in this clinical study are reimbursed for their time.

There are multiple groups for this study, so please call 1800 243 733 or email quoting “Gene Study” if you’d like more information.

  • 5
    Nights Inpatient Stay
  • 10
    Outpatient Visits

Minimum Eligibility Requirements:

  • Healthy CAUCASIAN males
  • Aged 21-50 years old
  • Body Mass Index (BMI) 19 - 30kg/m²
  • No significant medical conditions or medical history
  • Not currently taking prescription medications